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ABSTRACT  
Our objective was to show with two examples that a pharmacokinetic (PK) similarity analysis 
can be performed with nonlinear mixed effects models (NLMEM). We used two studies 
comparing different biosimilars: a three-way crossover trial on somatropin and a parallel 
group trial on epoetin alpha. For both datasets, NLMEM-based analysis was compared to 
non-compartmental analysis (NCA). As for NCA, we performed NLMEM-based equivalence 
Wald test on secondary parameters of the model: the area under the curve and the maximal 
concentration. Somatropin PK was described by a one-compartment model, epoetin alpha PK 
by a two-compartment model with linear and Michaelis-Menten elimination. For both studies, 
PK similarity was demonstrated by NCA and NLMEM. Both approaches led to similar 
results. Therefore, PK similarity data can be analyzed by both methods. NCA is an easier 
approach as it does not require data modelling but NLMEM leads to a better understanding of 
the underlying biological system. 
 
INTRODUCTION 
During the past two decades, an increasing fraction of pharmaceutical research and 
development (R&D) effort has been devoted to biologic drugs [1]. This is driven by evidence 
that biologics are bringing significant patient benefit in difficult-to-treat diseases such as 
rheumatoid arthritis and various cancers, and often changing the practice of medicine in these 
conditions. Biologics are typically expensive and place a large burden on shrinking health-
care budgets. Follow-on biologics or biosimilars are new biological medicinal products that 
are similar or comparable to the originator’s compound and that may be lower in price, and 
hence offer the promise of reduced healthcare expenditure [2]. However, biologics are more 
complex, containing mixtures of proteins with variations in molecular structure, versus the 
more homogeneous small molecule drugs. Generic versions of the latter can be easily 
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characterized by standard analytical techniques since they are chemically identical. 
Consequently, assessing the similarity between different formulations of biologics is more 
complex than assessing the equivalence between different formulations of chemical drugs [3]. 
It is not surprising therefore that the regulatory approval procedures vary from country to 
country regarding biosimilars.  Currently, there is no guideline for an abbreviated approval 
pathway of biosimilars from the Food and Drug Administration (FDA). The actual policy is 
decided on a “case-by-case” principle [4]. The European Medicines Agency (EMA) has more 
stringent approval requirements for biosimilars than for typical generic drugs [2]. As part of 
the required information, a pharmacokinetic (PK) bioequivalence study is usually performed 
as traditionally done for chemical drugs [5, 6], even if the study design is less straightforward. 
For example, a parallel group design may be necessary for  biologics with long half-life, as 
monoclonal antibodies [7]. Also, biosimilarity studies are often performed in patients, which 
raises several design challenges such as the selection of the study population, the number of 
doses or the treatment regimen. 
Generally, to analyze bioequivalence study data, the area under the curve (AUC) and the 
maximal concentration (Cmax) are estimated by non-compartmental analysis (NCA) and 
pharmacokinetic bioequivalence is assessed using these NCA estimates [6, 8]. Although 
nonlinear mixed effects models (NLMEM) are increasingly used in drug development for 
analyzing PK data (especially in sparse sampling design phase III trials) [9], there are only 
few published studies which use NLMEM to analyze bioequivalence trial data [10-17]. These 
authors used various statistical approaches to test bioequivalence with NLMEM but did not 
propose a general methodology. Model-based bioequivalence tests were studied through 
simulation for crossover trials [18-21]. Recently, we proposed a NLMEM-based 
bioequivalence analysis with a statistical approach similar to that recommended for NCA 
[21]. We showed that NLMEM-based Wald tests have good properties except for very sparse 
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designs and/or drugs with highly variable PK. NCA requires a large enough number of 
samples per subject to accurately determine AUC and Cmax and suffers from some caveats 
such as an inability to take into account nonlinear pharmacokinetics which is often exhibited 
by biologics [22].  NLMEM-based bioequivalence analysis would be more appropriate for 
such cases. 
In this paper, we describe the methodology to perform PK similarity analysis using NLMEM 
and illustrate this with data from two trials studying PK similarity of different biosimilars. 
Omnitrope (Sandoz GmbH, Kundl, Austria) was the first biosimilar recombinant growth 
hormone (or somatropin) approved in Europe, Japan, and Canada as well as in the US(1) and is 
the first of our examples. Somatropins are used to treat growth hormone deficiency, mainly in 
pituitary dwarfism. In the dataset we used, two formulations of this biosimilar, 3.3 mg/ml 
solution (formulation T1) and 5 mg/ml powder (formulation T2), were compared to the 
reference formulation, Genotropin (Pfizer Pharma GmbH, Karlsruhe, Germany). The second 
biologic is a recombinant human erythropoietin, or epoetin alpha. Epoetins alpha are used to 
treat, amongst others, anaemia in chronic renal failure patients as it regulates the maturation 
of erythroid-progenitor cells into red-blood cells. In the dataset we used, the test formulation 
Binocrit (Sandoz GmbH, Kundl, Austria) was compared to the reference formulation 
Erypo/Eprex (Janssen-Cilag GmbH, Neuss, Germany). The single dose, three-way crossover 
trial on somatropin was chosen to illustrate the NLMEM-based PK similarity analysis for 
“simple pharmacokinetics” and its utility for designs with fewer sampling times than usually 
done in NCA. The multiple dose parallel group trial on epoetin alpha was chosen to illustrate 
NLMEM-based PK similarity for “complex pharmacokinetics”. 
 
 
 
(1) Approved in US under 505(b)(2) 
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RESULTS 
Somatropin 
Data: 36 subjects were randomized, but one was prematurely withdrawn from the study as 
s/he did not present for the second treatment period. Thus, 35 subjects were included in the 
PK analysis. Overall measurements, 18 concentrations (1.4%) are below the limit of 
quantification (LOQ). These concentrations were measured at one of the two last sampling 
times. Based on pre and post-dose syringe weights, differences between the intended and 
actually administered dose were observed, possibly caused by slight variations in drug 
reconstitution and administration technique. Individual concentrations versus time profiles 
plotted for each formulation with a semi-logarithmic scale are displayed in the first column of 
Figure 1 for the complete dataset. 
[Figure 1 about here] 
PK modelling: Administered doses were used for the population PK analysis and the plasma 
concentrations below LOQ were taken into account in the parameter estimation by the SAEM 
algorithm implemented in MONOLIX software [23] which considers those data as left 
censored [24]. A one-compartment model with first-order absorption with a lag time, and 
first-order elimination best described the somatropin data of the reference formulation. The 
best statistical model included between-subject variability (BSV) for all PK parameters with a 
correlation between the clearance and the volume of distribution, and a combined (additive 
plus proportional) error model. Parameter estimates (except period and sequence effects) of 
the final model used for PK similarity analysis are displayed in Table 1 with their standard 
errors (SE). Precision of estimation was judged satisfactory for all parameters. Model 
evaluation plots are displayed in supplementary Figure S1 online and are satisfactory.  
We used the reference formulation estimates in the PFIM software [25] to determine the six 
sampling times per subject and per period of the optimized design (OD). The optimized 
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sampling times were: 1, 2, 8, 10, 20, and 24 h. For the empirical design (ED), the PK 
modeller chose the following sampling times: 1, 2, 4, 6, 12, and 24 h. Individual 
concentrations versus time profiles plotted for each formulation with a semi-logarithmic scale 
are displayed in the second and third columns of Figure 1 for the OD and ED datasets. For 
both sparse datasets, the additive parameter of the error model was fixed to 0.1, the estimated 
value for the complete dataset. Parameter estimates are displayed in supplementary Table S1 
online. Precision of estimation was judged satisfactory for all parameters and both sparse 
datasets. 
[Table 1 about here] 
PK similarity analysis: Table 2 summarizes the PK similarity analysis using NLMEM and 
NCA for the complete dataset and both sparse datasets (OD and ED). For AUC and Cmax, and 
the three datasets, the 90% confidence interval (CI)  ratio of AUC and Cmax for both 
formulations are within the equivalence interval 80-125%. Thus, PK similarity was 
demonstrated using both methodologies, for both formulations, and the three datasets. For 
both parameters and each dataset, the ratios and their 90% CI obtained by NCA or NLMEM 
are similar. For NLMEM estimates, the geometric means of AUC and Cmax are rather similar 
for the three datasets. For NCA estimates, the geometric means of AUC and Cmax are lower 
for OD dataset compared to complete and ED datasets. 
 [Table 2 about here] 
 
Epoetin alpha 
Data: Of the 80 subjects, 76 completed the study according to the protocol; 39 subjects 
received the reference formulation and 37 received the test. Due to subject bodyweight, the 
administered doses were between 5900 and 10,000 IU. There are no concentrations below 
LOQ. As expected, the epoetin alpha concentration versus time plotted for each formulation 
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with a semi-logarithmic scale showed a behaviour that is characteristic of a non-linear 
(capacity limited) elimination process [22] (Figure 2). 
[Figure 2 about here] 
PK modelling: A two-compartment model with linear and Michaelis-Menten elimination best 
described the epoetin alpha data of the reference formulation. To check our hypothesis on the 
elimination pathway, we compared the Bayesian Information Criteria (BIC) for this model 
versus the corresponding models with only linear (∆BIC=221) or Michaelis-Menten 
(∆BIC=11) elimination and confirmed that the mixed elimination pathway better described 
the data. The best statistical model included BSV for all PK parameters, with a correlation 
between the clearance and the volume of central compartment, and a proportional error 
model. Parameter estimates of the final model used for PK similarity analysis are displayed in 
Table 3 with their SE. Precision of estimation was judged satisfactory for all parameters. 
Figure 3 displays the visual predictive check (left) and the individual weighted residuals 
(IWRES) versus time (right) for each formulation group.  Most of the observations are in the 
90% prediction interval, and there are no major biases or trends in the IWRES plot. 
 [Table 3 about here] 
[Figure 3 about here] 
PK similarity analysis: Table 4 summarizes the PK similarity analysis using NLMEM and 
NCA. The 90% CI ratio of AUC and Cmax at steady state are within the equivalence interval 
80-125%, using NCA and NLMEM. For both parameters, the ratios and their 90% CI 
obtained by NCA or NLMEM are similar. The geometric means of Cmax are higher by NCA 
compared to NLMEM. The geometric means of AUC are lower by NCA compared to 
NLMEM. We estimated the formulation effect on the proportion of the dose nonlinearly 
eliminated (PDNE) by NLMEM-based analysis. The PDNE test/reference ratio was estimated 
as 94.6 with a 90% CI of [72.2; 123.9]. 
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[Table 4 about here] 
 
DISCUSSION 
In this study, we presented the results of a pharmacokinetic similarity analysis using NLMEM 
for two biologics: somatropin and epoetin alpha. Such analysis requires the collaboration of 
statisticians and pharmacokineticists [26]. We proposed a general methodology to perform 
such analysis for crossover and parallel designs and we compared the results to those obtained 
using traditional NCA. NLMEM-based equivalence tests were performed on secondary 
parameters of the models using the delta method or simulation to estimate the standard error 
of formulation effects. PK bioequivalence results from NCA and NLMEM are similar thereby 
demonstrating that NLMEM can be used for equivalence testing. 
For somatropin where the PK is simple, we also performed the analysis on two sparse datasets 
showing the importance of the design, especially for NCA. Indeed, NCA is highly sensitive to 
design, especially for the determination of Cmax and the computation of the terminal slope of 
the PK profile. The currently available tools to optimize the PK sampling times cannot take 
into account that equivalence test would be performed on Cmax.  Indeed, optimisation using 
the Fisher information matrix gives sampling times providing information on PK parameters 
of the model. This explains the difference in the NCA estimation of Cmax between OD dataset 
and the two other datasets. As shown in Dubois et al [27], with few samples per subject, NCA 
estimates can be biased, even if the PK similarity is still demonstrated. For somatropin, we 
adjusted the dose to estimate comparable AUC. This adjustment assumed a linear relation 
between dose and concentration which is wrong for nonlinear PK [22]. The dose adjustment 
is not necessary for the analysis by NLMEM as the dose is taken into account in the model. 
For epoetin alpha where the PK is complex, we estimated by NLMEM PDNE, a PK 
parameter that cannot be obtained by NCA. For nonlinear PK, clearance is not proportional to 
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AUC and NCA parameters are not very physiologically meaningful. Only the use of models 
allowed us to adequately study the nonlinear PK of the drug and its properties.  We would like 
to propose that parameters such as PDNE (or others perhaps linked to receptor occupancy) 
might be useful metrics particularly if they can be linked to clinically meaningful readouts of 
efficacy and safety [28].  
The estimation of parameters through NCA does not require the assumptions inherent in 
model-based approaches and tends to be more acceptable and familiar to Health Authorities. 
Despite claims that NCA is an “assumption-free” approach, it assumes linear 
pharmacokinetics. It was already shown that, in case of nonlinear pharmacokinetics, NCA can 
bias the comparability analysis of a biologic and that a model-based approach can correct it 
[29, 30]. Even for linear PK, the interpolation of the AUC between last sampling time and 
infinity could be problematic for atypical concentrations profiles [20].  Furthermore, NCA 
estimates are sensitive to data below LOQ. In standard analysis, pharmacokineticists usually 
omit these data. When analyzing data below LOQ in a model-based paradigm, various 
innovative approaches have been proposed [31, 32]. In this study, we used the SAEM 
algorithm implemented in MONOLIX [33] which takes into account data below LOQ [24]. 
Though the percentage of these data is small in our examples, it can be important such as their 
consideration impacts the parameter estimates. So, in circumstances as outlined above, 
NLMEM-based bioequivalence analysis might be more appropriate than NCA.  
In this paper, we proposed a PK similarity analysis using NLMEM in agreement with the 
guidelines recommendations for bioequivalence [5, 6]. For crossover trials, treatment, period 
and sequence effects were taken into account. For parallel and crossover trials, equivalence 
tests were performed on the treatment effect estimate. This latter type of PK similarity 
analysis requires the use of a robust algorithm such as SAEM because many parameters are 
estimated in these complex models. NLMEM take into account the knowledge accumulated 
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on the drug. Appropriately parameterised, such mathematical models can lead to a better 
understanding of the underlying biological system than the fully empirical NCA approach, 
especially for drugs with complex PK such as often biosimilars.  
 
METHODS 
Data 
Both studies were conducted according to the revised Helsinki Declaration and GCP 
guidelines. Data were described previously [34, 35]. 
 
Somatropin: The trial was a randomized, double-blind, single-dose, three-way crossover trial 
designed to demonstrate the bioequivalence of two novel somatropin formulations compared 
to a reference in healthy subjects. Thirty-six caucasian adults received octreotide for 
endogenous growth hormone suppression before somatropin administration. A single 
subcutaneous dose of 5 mg was administered at the beginning of each treatment period 
separated by a seven day wash-out period. Subjects were randomly allocated to one of the six 
sequences of treatment (R-T1-T2, R-T2-T1, T1-T2-R, T1-R-T2, T2-T1-R, T2-R-T1) knowing that 
there were six subjects by sequence. Blood samples for pharmacokinetic assessments were 
collected after each drug administration at 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20, and 24 h after 
dosing. Concentrations were measured by a chemiluminescent immunometric assay with a 
LOQ of 0.2 ng/mL.  
 
Epoetin alpha: The trial was a randomized, double-blind, multiple doses, parallel group trial 
designed to assess biosimilarity of epoetin alpha T compared to epoetin alpha R at steady 
state (after eleven doses). Eighty healthy caucasian males (forty by formulation) received 
intravenous doses of 100 IU/kg three times a week for four weeks. Blood samples for 
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pharmacokinetic assessments were collected at the following sampling times: day 1, at 0.01 h 
before dosing; days 8, 15, 19, 22 at the time of dose; day 24, at 0.5, 0.33, 0.17, and 0 h before 
dosing; and 0.08, 0.17, 0.25, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, and 36 h 
after dosing. Concentrations were determined using an enzyme immunoassay kit (EPO-
ELISA, Medac GmbH, Hamburg, Germany) with a LOQ of 2.5 mIU/mL.  
 
Nonlinear mixed effects modelling 
Model building using the reference data: Before performing the model-based PK similarity 
assessment, a population PK model was defined. To determine the structural and the 
statistical model (random effect matrices and residual error model), data from the reference 
formulation and information on the drug were used. We assumed exponential random effects 
for all PK profiles. Diagonal, block diagonal, and complete matrices were tested during model 
building. Regarding the error model, additive, proportional, and combined error models were 
tested. Models were compared by the Bayesian Information Criteria [36], standard goodness 
of fit plots and visual predictive checks. 
The final model was then used to fit all the data (reference and test formulations) and to 
perform the PK similarity analysis. For crossover trial, the structure of the within-subject 
variability (WSV) matrix was chosen to be identical to the structure of the BSV matrix. 
Population PK analyses were performed using the SAEM algorithm [37, 38] implemented in 
the MONOLIX software version 3.1R2 [33] (Monolix Software Project Group, Orsay, 
France) with log-likelihoods estimated by importance sampling. 
For somatropin, a one-compartment model with first order absorption and first order 
elimination was used with or without a lag time for the absorption [39]. The estimated PK 
parameters were CL/F (L/h), the apparent clearance of elimination, V/F (L), the apparent 
volume of distribution, ka (h-1), the absorption rate constant, tlag (h), the absorption lag time. 
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Epoetin alpha is a drug showing target-mediated drug disposition (TMDD) properties due to 
its specific and saturable internalization in erythroid progenitor cells [40, 41]. Fitting the 
TMDD PK model requires to assign some of the receptor-binding parameter values using 
results of in vitro receptor binding studies. When such data are not available, a Michaelis-
Menten approximation can be made [42-44]. The first considered structural model was a two-
compartment model with linear and Michaelis-Menten elimination. The corresponding 
differential equation system is defined in Equation 1 and 2:  
( )
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With Cc: the drug concentration in the central compartment, Cp: the drug concentration in the 
peripheral compartment, ,0)0()0( == pc CC and for each dosing time  
c
cc V
Dose
tCtC += −+ )()( .  
Modelling endogenous epoetin alpha production is complex and requires much more 
information on endogenous concentration than those available [44]. As in Ramakrishnan et al 
[45],  we assumed this production was not altered by the administration of recombinant 
human epoetin alpha. The endogenous baseline concentrations (C0) measured before any drug 
administration were taken into account considering that: )()( 0 tCCtC c+= , with C(t) the 
measured concentration. The estimated PK parameters were CLlin (L/h), the clearance of 
elimination, Q (L/h), the inter-compartmental clearance, Vc (L), the volume of distribution of 
the central compartment, Vp (L), the volume of distribution of the peripheral compartment, 
Vmax (IU/h), the maximum elimination rate from plasma, Km (IU/L), the plasma concentration 
at Vmax/2, C0 (IU/L), the endogenous baseline concentration. Km is equal to the equilibrium 
dissociation constant (KD) of the TMDD model and Vmax is proportional to the total receptor 
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concentration [42, 43]. We computed the proportion of the dose nonlinearly eliminated at 
steady state for each formulation. Since dttC
tCK
tVAUCCLDose c
cm
lin )()(
)(max ×
+
+×= ∫ , we 
deduced PDNE
Dose
AUCCLdttC
tCK
tV
DoseDose
AUCCL lin
c
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lin +
×
=×
+
+
×
= ∫ )()(
)(11 max  and 
Dose
AUCCLPDNE lin ×−= 1 . 
 
Sparse data for somatropin: From the somatropin dataset with twelve sampling times per 
subject and period, two ‘‘sparse’’ datasets were produced: the optimized and empirical design 
datasets. For both datasets, we fixed the number of samples to be half of the original design, 
i.e. six  per subject and period, and the sampling times were chosen among those of the 
complete dataset. To optimize the OD dataset sampling times, we used the PFIM software 
version 3.2 [25, 46] (Paris, France) with the parameter estimation of the reference formulation 
[47]. The Fedorov-Wynn algorithm was used to define the six sampling times for which the 
determinant of Fisher information matrix is maximum [48]. The ED dataset sampling times 
were determined by an experienced PK modeller before any knowledge on the data analysis, 
using the somatropin concentration versus time profiles for each formulation (see Figure 1), 
and knowing that we would estimate AUC and Cmax. 
 
PK similarity analysis 
NLMEM based approach: We show here how to perform a model-based equivalence 
analysis with a statistical approach similar to NCA but using NLMEM. For crossover trial 
(somatropin data), the statistical model included formulation, period, and sequence effects for 
all PK parameters. We considered that the reference formulation, the first period, and the first 
sequence (R-T1-T2) were the reference classes. For details on the statistical model, see Dubois 
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et al [27]. For parallel group trial (epoetin alpha data), formulation effects were added to all 
PK parameters.  
We assumed additive formulation, period and sequence effects on log parameters. We defined 
βT the formulation effect for a PK parameter. We performed equivalence tests on the estimate 
of βT using its SE and the Schuirman’s two one-sided tests procedure [49]. As we performed 
equivalence tests on secondary parameters of the structural model, we estimated the 
formulation effects from the fixed effects estimates or using simulation. The corresponding 
SE was computed by the delta method [50] or via simulation using the fixed effects estimates, 
and the Fisher information matrix estimate of the fixed effects.  We also estimated the 90% 
confidence interval of exp(βT) which corresponds to the 90% CI of the test/reference ratio for 
average considered parameter. Furthermore, as recommended in the guidelines, we reported 
the geometric mean and coefficient of variation (CV) of AUC and Cmax for each formulation. 
For somatropin, equivalence tests were performed on the formulation effects of AUC0-∞ and 
Cmax for each test formulation, with respect to the reference formulation. Formulation effects 
of AUC0-∞ and their SE were obtained directly from the formulation effects of the clearance 
and their SE. The formulation effects on Cmax were computing from the fixed effects 
estimates; their SE were computing by the delta method, as described in Dubois et al [27].  
For epoetin alpha, equivalence tests were performed on the formulation effects of AUC and 
Cmax at steady state. AUC were computed between the time of dose and the last sampling time 
of the dose (AUC0-36). Because of the Michaelis-Menten elimination, the structural PK model 
of epoetin alpha is written with ordinary differential equations. So, the formulation effects and 
their SE for these secondary parameters were estimated through simulations of concentration 
profiles. See supplementary information online for details on the simulation process. 
For somatropin, AUC0-∞ and Cmax were also the estimates of the geometric means, and the 
corresponding CV were estimated by the total variability, i.e. by the sum of the BSV and 
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WSV. For epoetin alpha, we computed by simulation the NLMEM-based geometric mean of 
AUC0-36 and Cmax for each formulation and their CV were obtained from their BSV (see 
supplementary information online). We also estimated the formulation effect on PDNE at 
steady state and the corresponding 90% CI. All simulations were performed using the R 
software version 2.11.0 (R foundation for Statistical Computing).  
 
Comparison to non-compartmental analysis: AUC and Cmax were calculated from the 
concentrations versus sampling time profiles by standard NCA using the R software. A 
combination of the linear and log-linear trapezoidal method was used, data below LOQ were 
omitted, three to six sampling times were used to compute the terminal slope [22]. When the 
administered dose differed from the intended dose, concentrations were divided by the ratio 
administered/intended dose before NCA estimation. For somatropin, AUC were computed 
from the time of dose to infinity (AUC0-∞). For epoetin alpha, AUC and Cmax were calculated 
at steady state, subtracting the endogenous baseline concentrations. AUC were calculated 
between the time of dose and the last sampling time (AUC0-36) which corresponds to the AUC 
at steady state (AUCss ). 
Equivalence testing was performed on log-transformed parameters. For crossover trial 
(somatropin data), a linear mixed effects model including formulation, period, sequence as 
fixed effects, and subject as random effect, was used. For parallel group trial (epoetin alpha 
data), a linear model with formulation effect was used. 90% CI of formulation effects were 
computed using a Student distribution with N-2 degrees of freedom (N: total number of 
subjects). Equivalence analyses were performed using the R software.  
 
SUPPLEMENTARY MATERIAL is linked to the online version of the paper at 
http://www.nature.com/cpt 
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FIGURE LEGENDS 
Figure 1: Somatropin concentration versus time (N=35) from the three-way crossover study 
for each formulation and the three datasets: the complete (left), the optimized design (middle) 
and the empirical design (right). Data from the same formulation but different periods are 
pooled. 
Figure 2: Epoetin alpha concentration versus time for each formulation (N=39 for the 
reference and N=37 for the test formulation) from the parallel group study 
Figure 3: Observed concentrations of epoetin alpha versus time with their 90% prediction 
interval (left), and individual weighted residuals (IWRES) versus time (right) for each 
formulation, reference (top), and test (bottom). 
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Table 1: Pharmacokinetic parameter estimates of somatropin (standard errors) from the three-
way crossover trial (complete dataset) 
 tlag (h) ka (h-1) V/F (L) CL/F (L/h) corrCL-V 
R 0.49 (0.07) 0.32 (0.07) 26.22 (0.1) 8.63 (0.03)  
1T
β  -0.22 (0.07) -0.2 (0.07) -0.12 (0.1) 0.01 (0.03)  
2T
β  -0.07 (0.06) -0.06 (0.08) 0.07 (0.11) 0.05 (0.03)  
BSV 0.33 (0.05) 0.18 (0.04) 0.44 (0.04) 0.23 (0.02) 0.81 
WSV 0.09 (0.04) 0.19 (0.03) 0.26 (0.03) 0.1 (0.01) 0.49 
a (ng/mL) 0.11 (0.02)     
b 0.14 (0.004)     
 
Period and sequence effects are not reported. a, additive error model parameter; b, proportional error model 
parameter; BSV, standard deviation for between-subject variability; 
1T
β , formulation effect for the test 
formulation T1; 2Tβ , formulation effect for the test formulation T2; corrCL-V, correlation between CL/F and V/F; 
R, fixed effects for the formulation of reference; WSV, standard deviation for within-subject variability. 
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Table 2: Pharmacokinetic similarity analysis for the somatropin data 
   Formulation R Formulation T1 Formulation T2  T1/R T2/R 
Dataset 
PK 
parameter 
Method 
Geometric 
mean 
CV 
(%) 
Geometric 
mean 
CV 
(%) 
Geometric 
mean 
CV 
(%) 
 Ratio 
(%) 
90% CI  
(%) 
Ratio 
(%) 
90% CI 
 (%) 
NLMEM 579.1 25.0 574 25.0 550.1 25.0  99.1 [95.0; 103.4] 95.0 [91.0; 99.1] AUC0-∞ 
(h.ng/mL) NCA 574.5 21.6 565.7 26.2 544 24.9  98.5 [94.1;103.1] 94.6 [90.4; 99.1] 
NLMEM 69.5 38.1 66.0 38.1 63.5 38.1  95.0 [87.5; 103.0] 91.4 [84.5; 98.8] 
C 
Cmax 
(ng/mL) NCA 73.7 34.5 70.0 31.9 68.6 37.9  95.3 [87.8;103. 3] 93.1 [85.9; 101.0] 
NLMEM 559.2 25.9 550.2 25.9 524.1 25.9  98.4 [94.1; 102.9] 93.7 [89.6; 98.0] AUC0-∞ 
(h.ng/mL) NCA 491.3 23.2 491.6 29.3 464.2 26.4  100.1 [95.6; 104.9] 94.4 [90.1; 98.9] 
NLMEM 68.6 38.8 63.7 38.8 60.7 38.8  92.9 [85.2; 101.3] 88.5 [81.4; 96.2] 
OD 
Cmax 
(ng/mL) NCA 59.7 42.2 55.1 45.3 54.0 47.8  92.6 [83.4; 102.8] 90.4 [81.4; 100.4] 
NLMEM 586.4 23.2 597.0 23.2 565.1 23.2  101.8 [97.8; 106] 96.4 [92.5; 100.4] AUC0-∞ 
(h.ng/mL) NCA 566.4 21.6 570 26 541.9 25.6  100.7 [96.1; 105.6] 95.6 [91.2; 100.2] 
NLMEM 70.8 38.2 68.1 38.2 65.2 38.2  96.2 [88.8; 104.1] 92.0 [85.0; 99.7] 
ED 
Cmax 
(ng/mL) NCA 72.4 34.3 68.6 32.4 67.5 37.0  95.0 [87.5; 103.2] 93.3 [86.0; 101.3] 
 
AUC0-∞, area under the curve between the time of dose and infinity; C, complete dataset; Cmax, maximal 
concentration; CV, coefficient of variation; CI, confidence interval; ED, empirical design dataset; NCA, non-
compartmental analysis; NLMEM, nonlinear mixed effects model; OD, optimized design dataset; PK, 
pharmacokinetic. 
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Table 3: Pharmacokinetic parameter estimates of epoetin alpha (standard errors) from the 
parallel group trial  
 Vc (L) Vp (L) 
CLlin 
(L/h) 
Q 
(L/h) 
Vmax 
(IU/h) 
Km 
(IU/L) 
C0 
(IU/L) clin VCL −
corr
 
R 4.05 
(0.14) 
2.58 
(0.46) 
0.36 
(0.06) 
0.34 
(0.06) 
341.22 
(38.09) 
90.83 
(17.74) 
8.26 
(0.34)  
βT 0.06 
(0.05) 
0.17 
(0.23) 
0.17 
(0.23) 
0.20 
(0.21) 
-0.07 
(0.16) 
-0.16 
(0.28) 
0.06 
(0.06)  
BSV 0.21 
(0.01) 
0.16 
(0.04) 
0.34 
(0.02) 
0.13 
(0.05) 
0.13 
(0.03) 
0.39 
(0.05) 
0.25 
(0.02) 0.9 (/) 
b 0.15 
(0.003)        
 
b, proportional error model parameter; BSV, standard deviation for the between-subject variability; βT, 
formulation effect for the test formulation; 
clin VCL −corr , correlation between CLlin and Vc;  R, fixed effects for 
the formulation of reference 
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Table 4: Pharmacokinetic similarity analysis for the epoetin alpha data 
 
AUCss, area under the curve between for the 11th dose; Cmax, maximal concentration for the 11th dose; CV, 
coefficient of variation; CI, confidence interval; NCA, non-compartmental analysis; NLMEM, nonlinear mixed 
effects model; PK, pharmacokinetic. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Formulation R Formulation T  T/R 
PK 
parameter 
Method 
Geometric 
mean 
CV 
(%) 
Geometric 
mean 
CV 
(%) 
 Ratio 
(%) 
90% CI 
(%) 
NLMEM 9,522.4 21.4 8,643.5 21.5  91.1 [83.6; 99.3] AUCss 
(h.mIU/mL) NCA 8,651.5 20.5 7,755.3 29.7  89.6 [85.7; 93.8] 
NLMEM 2,024.4 20.3 1,916.9 20.3  94.7 [87.5; 102.6] Cmax 
(mIU/mL) NCA 2,213.7 18.7 2,143.9 18.0  96.8 [93.3; 100.5] 
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Supplementary Figure S1: Observed concentrations of somatropin of the complete dataset 
versus time with their 90% prediction interval (left), and individual weighted residuals 
(IWRES) versus time (right) for each formulation, reference (top), test T1 (middle) and test T2 
(bottom). 
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Supplementary table S1: Pharmacokinetic parameter estimates of somatropin (standard 
errors) from the three-way crossover trial for both sparsified dataset 
  tlag (h) ka (h-1) V/F (L) CL/F (h/L) corrCL-V 
R 0.52 (0.07)  0.32 (0.04)  25.37 (6.62)  8.94 (0.96)  
1T
β  -0.28 (0.11)  -0.20 (0.07)  -0.10 (0.11)  0.02 (0.03)  
2T
β  -0.15 (0.08)  -0.04  (0.08)  0.14 (0.11)  0.06 (0.03)  
BSV 0.20 (0.06) 0.15 (0.04) 0.48 (0.04) 0.25 (0.02) 0.80 
WSV 0.07 (0.10) 0.17 (0.02) 0.23 (0.03) 0.07 (0.01) 0.71 
a (ng/mL) 0.1 (-)     
OD 
b 0.16 (0.007)     
       
R 0.49  (0.07)  0.32 (0.03)  25.29  (6.12)  8.53 (0.82)  
1T
β  -0.22 (0.09)  -0.18(0.07)  -0.10 (0.11)  -0.02 (0.02)  
2T
β  -0.05 (0.07)  -0.01  (0.09)  0.12  (0.12)  0.04 (0.02)  
BSV 0.26 (0.05) 0.15 (0.04) 0.47 (0.04) 0.22 (0.02) 0.86 
WSV 0.05 (0.08) 0.16 (0.03) 0.24 (0.03)  0.06 (0.01) 0.84 
a (ng/mL) 0.1 (-)     
ED 
b 0.18 (0.007)     
 
Period and sequence effects are not reported. b, proportional error model parameter; a, additive error model 
parameter (fixed to 0.1); BSV, standard deviation for between-subject variability; 
1T
β , formulation effect for the 
test formulation T1; 2Tβ , formulation effect for the test formulation T2; corrCL-V, correlation between CL/F and 
V/F; ED, empirical design dataset OD, optimised design dataset; R, fixed effects for the formulation of 
reference; WSV, standard deviation for within-subject variability. 
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Supplementary information to: Simulation for epoetin alpha dataset 
For the 1st and 11th dose, the formulation effects were estimated from 5000 concentration 
profiles simulated for each formulation on a fine time grid with a stepsize 0.01 h. To do so, 
first we simulated 5000 sets of PK parameters and their formulation effects using a Gaussian 
distribution with mean the fixed effects estimates, and covariance matrix the inverse of Fisher 
Information matrix estimate of the fixed effects. After simulating the concentration profiles, 
for each profile, we computed AUC using the linear trapezoidal method, and Cmax as the 
maximal observed concentration. For each dose, the formulation effect of AUC was estimated 
as the mean of the 5000 differences between the logarithm of the simulated AUC for the test 
and the reference formulations. The corresponding standard error was estimated as the 
standard deviation of the 5000 differences. The same methodology was used to estimate the 
formulation effect of Cmax and of the proportion of the dose nonlinearly eliminated. To 
compare to NCA, we also computed the NLMEM-based geometric mean of AUC0-∞ and Cmax 
for each formulation and their CV obtained from their BSV. For the 1st and 11th dose, and for 
each formulation, the population means of AUC and Cmax, and their CV were estimated from 
5000 concentration profiles. In that case, the 5000 sets of PK parameters were simulating 
using a log-normal distribution with mean the fixed effect estimates, and covariance matrix 
the BSV matrix estimates. After simulating the concentration profiles, for each dose and 
formulation, the population mean AUC and Cmax were computed as the mean of the 5000 
simulated AUC and Cmax, respectively. The corresponding standard deviation of BSV were 
estimated as the standard deviation of the 5000 simulated AUC or Cmax. 
